Moderna CEO Says RSV Vaccine Uptake In The U.S. Is Slower Than Anticipated
Portfolio Pulse from Benzinga Newsdesk
Moderna's CEO announced that the uptake of their RSV vaccine in the U.S. is slower than expected, as discussed at an investor conference.
September 12, 2024 | 3:52 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Moderna's CEO revealed that the RSV vaccine uptake in the U.S. is slower than anticipated, which could impact the company's revenue projections.
The slower uptake of the RSV vaccine could lead to lower than expected revenues for Moderna, affecting short-term stock performance. This news is significant for investors as it directly impacts the company's financial outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90